Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-25T17:02:13.563Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychoticism and Paranoid Ideation in Patients With Nonpsychotic Major Depressive Disorder: Prevalence, Response to Treatment, and Impact on Short- and Long-Term Treatment Outcome

Published online by Cambridge University Press:  07 November 2014

Christina M. Dording ,
David Mischoulon ,
Tracie M. Goodness ,
Lee Baer ,
Alisabet Clain ,
Jonathan W. Stewart ,
John D. Matthews ,
Patrick J. McGrath ,
Andrew A. Nierenberg  and
Maurizio Fava
...Show all authors
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective/Introduction: We sought to characterize the impact of the 90-item Symptom Checklist (SCL-90) subscales for paranoid ideation (PI) and psychoticism (P) in patients with major depressive disorder (MDD), on acute anti-depressant response and on relapse prevention.

Methods: Subjects with Structured Clinical Interview for DSM Disorders-diagnosed non-psychotic MDD were recruited into a clinical trial of open-label fluoxetine 10–60 mg/day for 12 weeks, followed by double-blind randomization of responders (n=262) to fluoxetine continuation or placebo for 12 months. PI and P were assessed with the patient-rated SCL-90. The association of these symptoms with response to treatment was assessed by logistic regression.

Results: We found significant decreases in PI and P during acute treatment phase for fluoxetine responders and nonresponders, although only 10.3% and 7.5% of patients experienced a ≥50% reduction in PI and P scores, respectively. Neither PI nor P scores significantly predicted time to relapse. P scores predicted a lower response rate to treatment with fluoxetine.

Discussion: The results of the present study suggest that there is a significant relationship between the presence of psychoticism in patients with nonpsychotic MDD, and the likelihood of overall depressive symptom improvement following a trial of monotherapy with fluoxetine.

Conclusion: An increased burden of psychoticism in depressed subjects may confer poorer response to fluoxetine, but not increased risk of relapse among fluoxetine responders.

Type
Original Research
Information
CNS Spectrums , Volume 15 , Issue 8 , August 2010 , pp. 515 - 521
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
2.Schatzberg, AF and Rothschild, AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149:733–745.Google Scholar
3.Rothschild, AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003;53(8):680–90.Google Scholar
4.Charney, DS, Nelson, J. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry. 1981;138:328–333.Google ScholarPubMed
5.Keller, J, Schatzberg, AF, Maj, M. Current issues in the classification of psychotic major depression. Schizophr Bull. 2007;33(4):877–85.CrossRefGoogle ScholarPubMed
6.Coryell, W. Psychotic depression. J Clin Psychiatry. 1996;57(suppl 3):27–3.Google Scholar
7.Wijkstra, J, Burger, H, van den Broek, WW, et al. Pharmacological Treament of Unipolar psychotic Depression. A randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. J Affect Disord. 2010;123(1–3):238–242.CrossRefGoogle Scholar
8.Rothschild, AJ, Williamson, DJ, Tohen, MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004;24(4):365–373.Google Scholar
9.Spiker, DG, Weiss, JC, Dealy, RS, et al. The pharmacologic treatment of delusional depression. Am J Psychiatry. 1985;142(4):430–436.Google ScholarPubMed
10.American Psychiatric Association: Practice guideline for the treatment of major depressive disorder (revision). Am J Psychiatry. 2000;157(suppl 4).Google Scholar
11.Simpson, GM, El Sheshai, A, Rady, A, Kingsbury, SJ, Fayek, M. Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. J Clin Psychiatry. 2003;64(8):959–965.Google Scholar
12.Meyers, BS, Flint, AJ, Rothschild, AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009;66(8):838–847.CrossRefGoogle Scholar
13.Zanardi, R, Franchini, L, Gasperini, M, Perez, J, Smeraldi, E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry. 1996;153(12):1631–1633.Google ScholarPubMed
14.Zanardi, R, Franchini, L, Serretti, A, Perez, J, Smeraldi, E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry. 2000;61(1):26–29.Google Scholar
15.Englisch, S, Knopf, U, Scharnholz, B, Kuwilsky, A, Deuschle, M, Zink, M. Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial. J Psychopharmacol. (In press).Google Scholar
16.Birkenhager, TK, van den Broek, WW, Mulder, PG, Moleman, P, Bruijn, JA. Efficacy of imipramine in psychotic versus nonpsychotic depression. J Clin Psychopharmacol. 2008;28(2):166–170.CrossRefGoogle ScholarPubMed
17.van de Broek, WW, Birkenhäger, TK, Mulder, PG, Bruijn, JA, Moleman, P. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology (Berl). 2004;175(4)481–486.Google Scholar
18.Spiker, DG, Dealy, RS, Hanin, I, Weiss, JC, Kupfer, DJ. Treating delusional depressives with amitriptyline. J Clin Psychiatry. 1986;47(5):243–246.Google ScholarPubMed
19.Spiker, DG, Kupfer, DJ. Placebo response rates in psychotic and nonpsychotic depression. J Affect Disord. 1988;14(1):21–23.CrossRefGoogle ScholarPubMed
20.Bruijn, JA, Moleman, P, Mulder, PG, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology (Berl). 1996;127(3):231–237.Google Scholar
21.Mulsant, BH, Sweet, RA, Rosen, J, et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry. 2001;62(8):597–604.Google Scholar
22.Künzel, HE, Ackl, N, Hatzinger, M, et al. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol - A double-blind multicenter trial. J Psychiatr Res. (In press).Google Scholar
23.Janicak, PG, Pandey, GN, Davis, JM, Boshes, R, Bresnahan, D, Sharma, R. Response of psychotic and nonpsychotic depression to phenelzine. Am J Psychiatry. 1988;145(1):93–95.Google Scholar
24.Nelson, JC, Mazure, CM, Jatlow, PI. Characteristics of desipramine-refractory depression. J Clin Psychiatry. 1994;55(1):12–19.Google ScholarPubMed
25.Benazzi, F. Is there a continuity between bipolar and depressive disorders? Psychother Psychosom. 2007;76(2):70–76.CrossRefGoogle Scholar
26.Dording, CM, Sinicropi-Yao, L, Papakostas, G, et al. The response of psychotic-like symptoms to fluoxetine in non-psychotic major depressive disorder. Nord J Psychiatry. 2009;11:1–6.Google Scholar
27.McGrath, P, Stewart, J, Quitkin, F, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163:1542–1548.Google Scholar
28.Derogatis, L, Lipman, R, Rickels, K, et al. The Hopkins symptom checklist (HSCL): a self-report symptom inventory. J App Behav Sci. 1974;19:1–15.Google Scholar
29.First, M, Spitzer, R, Gibbon, M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders–Patient Edition (SCID-I/P, Version 2.0). New York, NY: biometrics Research Department, New York State Psychiatric Institute; 1995.Google Scholar
30.Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; revised. DHEW Pub. No. (ADM) 1976;76–338.Google Scholar
31.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.Google Scholar
32.Derogatis, LR. SCL-90: Administration, Scoring, and Procedures Manual. 3rd ed. Minneapolis, MN: National Computer Systems; 1994.Google Scholar
33.Overall, JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10;790–812.CrossRefGoogle Scholar
34.Meyers, BS, English, J, Gabriele, M, et al. A delusion assessment scale for psychotic major depression: Reliability, validity, and utility. Biol Psychiatry. 2006;60(12):1336–1342.Google Scholar